Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology forecast - 2030" drug pipeline report has been added to ResearchAndMarkets.com's offering.

This 'Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Chronic Obstructive Pulmonary Disease (COPD) Detailed Epidemiology Segmentation

• The total diagnosed prevalent population of Chronic Obstructive Pulmonary Disease (COPD) in seven major markets was found to be 31,730,590 in 2020 and is anticipated to increase in 2030.
• The estimates suggest a higher diagnosed prevalence of COPD in the United States with 17,455,605 diagnosed cases in 2020, which might increase in 2030.
• The majority of cases of Chronic Obstructive Pulmonary Disease (COPD) are female as compared to male, in the US. But in EU-5 and Japan the diagnosed cases of males represents majority of the cases.
• In the epidemiology model of Chronic Obstructive Pulmonary Disease (COPD), there are multiple age groups referred ranging from 18-44 years, 45-54 years, 55-64 years, 64-74 years, and 75+ years, for COPD in the US. The highest was 4,601,558 in the age group 55-64 years, in 2020.
• In 2020, the US had 2,967,453, 8,727,802, 4,538,457 and 1,221,892 cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4.

Key Questions Answered

• What are the disease risk, and burden of Chronic Obstructive Pulmonary Disease (COPD)?
• What is the historical Chronic Obstructive Pulmonary Disease (COPD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Chronic Obstructive Pulmonary Disease (COPD) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Obstructive Pulmonary Disease (COPD)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Obstructive Pulmonary Disease (COPD) during the forecast period (2021-2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Executive Summary of Chronic Obstructive Pulmonary Disease (COPD)

4 Key Events

5 Disease Background and Overview

5.1 Introduction

5.2 Factors That Influence Disease Development and Progression

5.3 Symptoms

5.4 Types

5.5 Classification

5.6 Stages

5.7 Pathology, Pathogenesis, and Pathophysiology

5.8 Diagnosis

5.8.1 Differential Diagnosis

5.8.2 Diagnostic Algorithm

5.8.3 Diagnostic Guidelines

5.8.3.1 Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

5.8.3.2 Chronic Obstructive Pulmonary Disease: Diagnosis and Management

5.8.3.3 Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease) 3rd edition

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Methodology of Epidemiology

6.3 Assumptions and Rationale: 7MM

6.3.1 US Assumptions and Rationale

6.3.2 EU5 Assumptions and Rationale

6.3.3 JP Assumptions and Rationale

6.4 Total Diagnosed Prevalent Patient Population of Chronic Obstructive Pulmonary Disease in the 7MM

6.5 The United States

6.6 Europe

6.7 Japan

7 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6aoccx